Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction

References

• Blair HA. Crizanlizumab: first Approval. Drugs. 2020;80(1):79–12. doi:10.1007/s40265-019-01254-2.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. New England Journal of Medicine. 2017;376(5):429–39. doi:10.1056/NEJMoa1611770.
   PubMed Web of Science ®Google Scholar
• Du Y, Walsh A, Ehrick R, Xu W, May K, Liu HC. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs. 2012;4(5):578–85. doi:10.4161/mabs.21328.
   PubMed Web of Science ®Google Scholar
• Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides - succinimide-linked reactions that contribute to protein-degradation. Journal of Biological Chemistry. 1987;262(2):785–94. doi:10.1016/S0021-9258(19)75855-4.
   PubMed Web of Science ®Google Scholar
• Stephenson RC, Clarke S. Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. Journal of Biological Chemistry. 1989;264(11):6164–70. doi:10.1016/S0021-9258(18)83327-0.
   PubMed Web of Science ®Google Scholar
• Aswad DW, Paranandi MV, Schurter BT. Isoaspartate in peptides and proteins: formation, significance, and analysis. Journal of Pharmaceutical and Biomedical Analysis. 2000;21(6):1129–36. doi:10.1016/S0731-7085(99)00230-7.
   PubMed Web of Science ®Google Scholar
• Potter SM, Henzel WJ, Aswad DW. In-vitro aging of Calmodulin generates isoaspartate at multiple Asn-Gly and Asp-Gly sites in calcium-binding domain-II, domain-III, and domain-IV. Protein Science. 1993;2(10):1648–63. doi:10.1002/pro.5560021011.
   PubMed Web of Science ®Google Scholar
• Oliyai C, Borchardt RT. Chemical pathways of peptide degradation .IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharmaceutical Research. 1993;10(1):95–102. doi:10.1023/A:1018981231468.
   PubMed Web of Science ®Google Scholar
• Brennan TV, Clarke S. Effect of adjacent histidine and cysteine residues on the spontaneous degradation of asparaginyl-containing and aspartyl-containing peptides. International Journal of Peptide and Protein Research. 1995;45(6):547–53. doi:10.1111/j.1399-3011.1995.tb01318.x.
   PubMedGoogle Scholar
• Athiner L, Kindrachuk J, Georges F, Napper S. The influence of protein structure on the products emerging from succinimide hydrolysis. Journal of Biological Chemistry. 2002;277(34):30502–07. doi:10.1074/jbc.M205314200.
   PubMed Web of Science ®Google Scholar
• Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharmaceutical Research. 2007;24(6):1145–56. doi:10.1007/s11095-007-9241-4.
   PubMed Web of Science ®Google Scholar
• Xiao G, Bondarenko PV, Jacob J, Chu GC, Chelius D. 18 O labeling method for identification and quantification of succinimide in proteins. Analytical Chemistry. 2007;79(7):2714–21. doi:10.1021/ac0617870.
   PubMed Web of Science ®Google Scholar
• Chelius D, Rehder DS, Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Analytical Chemistry. 2005;77(18):6004–11. doi:10.1021/ac050672d.
   PubMed Web of Science ®Google Scholar
• Capasso S, Kirby AJ, Salvadori S, Sica F, Zagari A. Kinetics and mechanism of the reversible isomerization of aspartic-acid residues in tetrapeptides. Journal of the Chemical Society-Perkin Transactions. 1995;2(3):437–42. doi:10.1039/p29950000437.
   Google Scholar
• Xie ML, VanderVelde D, Morton M, Borchardt RT, Schowen RL. pH-induced change in the rate-determining step for the hydrolysis of the Asp/Asn-derived cyclic-imide intermediate in protein degradation. Journal of the American Chemical Society. 1996;118(37):8955–56. doi:10.1021/ja9606182.
   Web of Science ®Google Scholar
• Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Advanced Drug Delivery Reviews. 2006;58(5–6):686–706. doi:10.1016/j.addr.2006.03.011.
   PubMed Web of Science ®Google Scholar
• Yan BX, Steen S, Hambly D, Valliere-Douglass J, Bos TV, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. Journal of Pharmaceutical Sciences. 2009;98(10):3509–21. doi:10.1002/jps.21655.
   PubMed Web of Science ®Google Scholar
• Cacia J, Keck R, Presta LG, Frenz J. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. Biochemistry. 1996;35(6):1897–903. doi:10.1021/bi951526c.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Wallace A, Balland A. Separation of populations of antibody variants by fine tuning of hydrophobic-interaction chromatography operating conditions. Journal of Chromatography A. 2008;1214(1–2):81–89. doi:10.1016/j.chroma.2008.10.078.
   PubMed Web of Science ®Google Scholar
• Ouellette D, Chumsae C, Clabbers A, Radziejewski C, Correia I. Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule. MAbs. 2013;5(3):432–44. doi:10.4161/mabs.24458.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K Chen AB, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. Journal of Chromatography B. 2001;752(2):233–45. doi:10.1016/S0378-4347(00)00548-X.
   PubMedGoogle Scholar
• Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, et al. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma 2 antibody highlights the role avidity plays in antibody activity. Biochemistry. 2008;47(8):2518–30. doi:10.1021/bi7018223.
   PubMed Web of Science ®Google Scholar
• Arvinte T, Palais C, Green-Trexler E, Gregory S, Mach H, Narasimhan C, Shameem AB. Aggregation of biopharmaceuticals in human plasma and human serum Implications for drug research and development. MAbs. 2013;5(3):491–500. doi:10.4161/mabs.24245.
   PubMed Web of Science ®Google Scholar
• Bults P, Bischoff R, Bakker H, Gietema JA, van de Merbel NC. LC-MS/MS-based monitoring of In vivo protein biotransformation: quantitative determination of trastuzumab and its deamidation products in human plasma. Analytical Chemistry. 2016;88:1871–77.
   PubMed Web of Science ®Google Scholar
• Hurtado PP, O’Connor PB. Differentiation of isomeric amino acid residues in proteins and peptides using mass spectrometry. Mass Spectrometry Reviews. 2012;31(6):609–25. doi:10.1002/mas.20357.
   PubMed Web of Science ®Google Scholar
• Cournoyer JJ, Pittman JL, Ivleva VB, Fallows E, Waskell L, Costello CE, O'Connor PB. Deamidation: differentiation of aspartyl from isoaspartyl products in peptides by electron capture dissociation. Protein Science. 2005;14(2):452–63. doi:10.1110/ps.041062905.
   PubMed Web of Science ®Google Scholar
• O’Connor PB, Cournoyer JJ, Pitteri SJ, Chrisman PA, McLuckey SA. Differentiation of aspartic and isoaspartic acids using electron transfer dissociation. Journal of the American Society for Mass Spectrometry. 2006;17(1):15–19. doi:10.1016/j.jasms.2005.08.019.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Carrasco M. Modern proteomics - sample preparation, analysis and practical applications preface. In: Mirzaei H, Carrasco M, editors. Modern proteomics - sample preparation, analysis and practical applications. 2016. p. V–VI.
   Google Scholar
• Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Current Pharmaceutical Biotechnology. 2008;9(6):468–81. doi:10.2174/138920108786786402.
   PubMed Web of Science ®Google Scholar
• Liu M, Cheetham J, Cauchon N, Ostovic J, Ni WQ, Ren D, Zhou ZS. Protein isoaspartate methyltransferase-mediated 18 O-labeling of isoaspartic acid for mass spectrometry analysis. Analytical Chemistry. 2012;84(2):1056–62. doi:10.1021/ac202652z.
   PubMed Web of Science ®Google Scholar
• Klaene JJ, Ni WQ, Alfaro JF, Zhou ZS. Detection and quantitation of succinimide in intact protein via hydrazine trapping and chemical derivatization. Journal of Pharmaceutical Sciences. 2014;103(10):3033–42. doi:10.1002/jps.24074.
   PubMed Web of Science ®Google Scholar
• Fujii N, Sakaue H, Sasaki H, Fujii N. A rapid, comprehensive liquid chromatography-mass spectrometry (LC-MS)-based survey of the asp isomers in crystallins from human cataract lenses. Journal of Biological Chemistry. 2012;287(47):39992–02. doi:10.1074/jbc.M112.399972.
   PubMed Web of Science ®Google Scholar
• Fujii N, Takata T, Fujii N, Aki K, Sakaue H. D-Amino acids in protein: the mirror of life as a molecular index of aging. Biochimica Et Biophysica Acta-Proteins and Proteomics. 2018;1866(7):840–47. doi:10.1016/j.bbapap.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Riggs DL, Gomez SV, Julian RR. Sequence and solution effects on the prevalence of d -Isomers produced by deamidation. Acs Chemical Biology. 2017;12(11):2875–82. doi:10.1021/acschembio.7b00686.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Jones L, Shpektor D, Kodama P, Waggace A, Balland A, Bailey R, Zhang Y. Separation and characterization of an IgG2 antibody containing a cyclic imide in CDR1 of light chain by hydrophobic interaction chromatography and mass spectrometry. Analytical Chemistry. 2008;80(9):3168–74. doi:10.1021/ac702245c.
   PubMed Web of Science ®Google Scholar
• Doyle HA, Zhou J, Wolff MJ, Harvey BP, Roman RM, Gee RJ, Koski RA, Mamula MJ. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. Journal of Biological Chemistry. 2006;281(43):32676–83. doi:10.1074/jbc.M604847200.
   PubMed Web of Science ®Google Scholar
• Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity. 2007;40(2):131–37. doi:10.1080/08916930601165180.
   PubMed Web of Science ®Google Scholar
• Cao MY, Xu WC, Niu B, Kabundi I, Luo HB, Prophet M, Chen W, Liu D, Saveliev SV, Urh M, et al. An automated and qualified platform method for site-specific succinimide and deamidation quantitation using low-pH peptide mapping. Journal of Pharmaceutical Sciences. 2019;108(11):3540–49. doi:10.1016/j.xphs.2019.07.019.
   PubMed Web of Science ®Google Scholar
• Du Y, Wang FQ, May K, Xu W, Liu HC. Determination of deamidation artifacts introduced by sample preparation using 18 O-labeling and tandem mass spectrometry analysis. Analytical Chemistry. 2012;84(15):6355–60. doi:10.1021/ac3013362.
   PubMed Web of Science ®Google Scholar
• Liu SS, Moulton KR, Auclair JR, Zhou ZS. Mildly acidic conditions eliminate deamidation artifact during proteolysis: digestion with endoprotease Glu-C at pH 4.5. Amino Acids. 2016;48:1059–67. doi:10.1007/s00726-015-2166-z.
   PubMed Web of Science ®Google Scholar
• Schmid I, Bonnington L, Gerl M, Bomans K, Thaller AL, Wagner K, Schlothauer T, Falkenstein R, Zimmermann B, Kopitz J, et al. Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions. Communications Biology. 2018;1. doi:10.1038/s42003-018-0032-8.
   PubMed Web of Science ®Google Scholar
• Griaud F, Denefeld B, Lang M, Hensinger H, Haberl P, Berg M. Unbiased in-depth characterization of CEX fractions from a stressed monoclonal antibody by mass spectrometry. MAbs. 2017;9(5):820–30. doi:10.1080/19420862.2017.1313367.
   PubMed Web of Science ®Google Scholar